Al Sandrock, new member of Voyager's board of directors (Biogen via YouTube)

Al San­drock makes his first post-Bio­gen move, join­ing turn­around ef­fort at a trou­bled gene ther­a­py start­up

A few years ago, when Bio­gen was look­ing for its next block­buster, the biotech re­port­ed­ly con­sid­ered buy­ing out Voy­ager Ther­a­peu­tics.

The deal made in­tu­itive sense. Voy­ager fo­cused on gene ther­a­pies for neu­ro­log­i­cal con­di­tions, com­bin­ing a tech­nol­o­gy in which Bio­gen had shown oc­ca­sion­al en­thu­si­asm with a field in which Bio­gen con­sid­ered them­selves the lead­ing ex­pert. But, as STAT re­port­ed last year, Bio­gen’s con­ser­v­a­tive board nixed it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.